CBD study for infant seizures halted early
NCT ID NCT04485104
First seen Nov 01, 2025 · Last updated May 08, 2026 · Updated 27 times
Summary
This study tested a cannabidiol (CBD) oral solution in children under 2 years old with tuberous sclerosis complex, Dravet syndrome, or Lennox-Gastaut syndrome whose seizures were not well-controlled. The main goals were to check safety and how the body processes the drug. Only 3 participants were enrolled before the study was terminated, so no firm conclusions can be drawn.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SEIZURE IN PARTICIPANTS WITH TUBEROUS SCLEROSIS COMPLEX are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Clinical Trial Site
Little Rock, Arkansas, 72202, United States
-
Clinical Trial Site
Los Angeles, California, 90095, United States
-
Clinical Trial Site
Chicago, Illinois, 60611, United States
-
Clinical Trial Site
Boston, Massachusetts, 02114, United States
-
Clinical Trial Site
Cincinnati, Ohio, 45229, United States
-
Clinical Trial Site
Houston, Texas, 77030, United States
-
Clinical Trial Site
Florence, 50139, Italy
-
Clinical Trial Site
Genova, 16147, Italy
-
Clinical Trial Site
Rome, 00165, Italy
-
Clinical Trial Site
Barcelona, 08950, Spain
-
Clinical Trial Site
Madrid, 28034, Spain
Conditions
Explore the condition pages connected to this study.